2 recruiting, 1 not yet recruiting, 1 unknown. 3 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Unknown 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Paolo Ghia: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens Venetoclax - Chronic Lymphocytic Leukemia | Phase 4 | Not yet recruiting | Paolo Ghia | 30 | 2023-11-01 | 2023-10-03 |
| Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) Venetoclax, Rituximab, Ibrutinib - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Recruiting | Paolo Ghia | 55 | 2022-09-19 | 2023-10-04 |
| Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL Ibrutinib and obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Recruiting | Paolo Ghia | 53 | 2021-12-13 | 2023-10-03 |
| Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Venetoclax, Imbruvica Oral Product - Chronic Lymphocytic Leukemia | Phase 2 | Unknown | Paolo Ghia | 31 | 2017-11-08 | 2023-10-03 |
Leukemia, Lymphocytic, Chronic, B-Cell (4)
venetoclax (3) · ibrutinib (2) · Biopsy, Needle (1) · Rituximab (1) · obinutuzumab (1)
Italy (3)